Quantitative prediction of OATP1B-mediated drug–drug interactions using endogenous biomarker coproporphyrin I
Author:
Affiliation:
1. Japan Pharmaceutical Manufacturers Association, Tokyo, Japan
2. Torii Pharmaceutical Co., Ltd, Osaka, Japan
3. Asahi Kasei Pharma Corporation, Shizuoka, Japan
4. Shionogi & Co., Ltd, Osaka, Japan
5. Bayer Yakuhin, Ltd, Osaka, Japan
Publisher
Informa UK Limited
Subject
Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/00498254.2022.2085210
Reference42 articles.
1. A new look at the statistical model identification
2. Expanded Physiologically‐Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction
3. The interaction of diltiazem with lovastatin and pravastatin*
4. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers
5. Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model;Drug Metabolism and Pharmacokinetics;2024-02
2. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor;Journal of Pharmaceutical Sciences;2023-09
3. Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies;The Journal of Clinical Pharmacology;2023-05-10
4. Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures;Clinical Pharmacology & Therapeutics;2022-08-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3